Skip to content
Business
Prognosis

Moderna’s Omicron Shot Yields Antibodies Against New Variants

  • BA.4 and BA.5 variants accounted for 35% of US cases in June
  • Results to be submitted to regulators, CEO Bancel says
A healthcare worker fills a syringe with a dose of the Moderna Covid-19 vaccine in Richmond, California.

A healthcare worker fills a syringe with a dose of the Moderna Covid-19 vaccine in Richmond, California.

Photographer: David Paul Morris/Bloomberg
Updated on

Moderna Inc.’s omicron-targeting vaccine triggered the production of antibodies against the strain’s newest variants, though the immune response was less robust than seen with the original version that emerged late last year.  

Everyone given Moderna’s lead omicron immunization generated neutralizing antibodies against BA.4 and BA.5 in the latest trial involving about 800 people, the Cambridge, Massachusetts-based company said in a statement. However, the amount of antibodies induced against the newer strains was lower than the shot produced against the original version of omicron.